Page 60 - Diamicron MR MIG Cycle 2(20-21) Final

1/28/2021

Combine the solutions to multiply life-saving benefits

Reduction in renal events* in

Separate and combined effects of intensive glucose control strategy (based on
gliclazide MR) and blood pressure–lowering on new or worsening nephropathy.
Relative risk reduction (%) by 3 randomized treatment groups: intensive glucose
control (based on gliclazide MR) vs standard glucose control 1 , PER-IND vs 20 IF 0551 NA
placebo 2 , intensive glucose control (based on gliclazide MR) and PER-IND vs
standard glucose control and placebo 3 . Elaborated from published data. 1-3
This study is not listed in the EU SmPC of Preterax ® and Diamicron ® , to be validated by local RA. * This indication does not correspond to the EU indication of Preterax ® and Diamicron ® , to be validated by local RA.
1. Patel A et al. N Engl J Med. 2008;358(24):2560-2572. 2. Patel A et al. Lancet. 2007;370:829-840. 3. Chalmers J et al. J Cardiovasc Pharmacol. 2010;55:340-347.
DMR-C1-2021-002
19 20

Combine the solutions to multiply life-saving benefits
ဆရာတိ ့ ့ Diabetic Hypertension Patients ေတွမ�ာ Diamicron MR နဲ ့ Preterax သာ
�ရဲ
Reduction in cardiovascular mortality* in ေပါင်းေပးလိက်မယ်ဆိရင် Patients ေတွရမယ့် Life Saving Benefits ကိ ဆတိး ရ��လာမ�ာပါ။
�
ိ
�
�
�
ADVANCE Study မာ သက်ေသြပထားတ့အတိင်း CV Death ကိ -24% နဲ ့ Nephropathy ကိ� -
�
�
ဲ
�
33% ထိေလ�ာ့ချေပးပါတယ။ ်
Separate and combined effects of intensive glucose control strategy (based on
gliclazide MR) and blood pressure–lowering on cardiovascular death. Relative
risk reduction (%) by 3 randomized treatment groups: intensive glucose control
(based on gliclazide MR) vs standard glucose control 1 , PER-IND vs placebo 2 ,
intensive glucose control (based on gliclazide MR) and PER-IND vs standard
glucose control and placebo 3 . Elaborated from published data. 1-3 .
20 IF 0551 NA
This study is not listed in the EU SmPC of Preterax ® and Diamicron ® , to be validated by local RA. * This indication does not correspond to the EU indication of Preterax ® and Diamicron ® , to be validated by local RA.
1. Patel A et al. N Engl J Med. 2008;358(24):2560-2572. 2. Patel A et al. Lancet. 2007;370: 829-840. 3. Chalmers J et al. J Cardiovasc Pharmacol. 2010;55:340-347.
For reference 2, ADVANCE was an international, large-scale, 2x2 factorial, randomized clinical trial conducted in 11 140 patients with type 2 diabetes who were assigned to perindopril 2 mg/indapamide 0.625 mg and after 3 months the doses were doubled to perindopril 4 mg/indapamide 1.25
mg; or a placebo on top of conventional therapies (73% of patients were treated with a RAAS inhibitor; control group); Preteraxreduced the primary outcome, the composite of major macrovascular and microvascular events, by 9% vs placebo (P=0.041); mean follow-up 4.3 years.
For reference 1, the type 2 diabetes patients were randomly assigned to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. As a result, the
strategy of intensive glucose control (involving gliclazide modified release) yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. Median follow-up of 5 years.
For reference 3, the fixed combination of perindopril and indapamide in the same patients produced substantial benefits in reducing all-cause and cardiovascular mortality, the primary combined outcome of macro- or microvascular events, total coronary events, and total renal events
DMR-C1-2021-002
21 22
Combine solutions for patients
with diabetes and hypertension • ေန ့ စဥ ကမာေပါ်မာ Diamicron MR နဲ ့Preterax ေသာကေနတဲ့ Diabetes နဲ ့Hypertension Patients
်
်
�
�
်
ိ
ေတွ အများ�ကီး��ပါတယ။ ဆရာ/အမ တိ ့ �လည်း Diabetes နဲ ့ Hypertension Patients ေတွမ�ာ
�
်
�
Diamicron MR နဲ ့ Preterax ကိ� အတတ ေပးြခင်းြဖင့ Patients ေတရ ့ ေသချာတဲ့ အနာဂတ်ကိ�
ွ
ဲ
ယံ��ကည်စွာဆံးြဖတ်ေပးလိ ့ရပါတယ်။
�
�
�
ံ
• ဆရာ/အမတိ ့ �လည်း လက်ခမယ်လ ့ ိထင်ပါတယ်။
• ေန ့ စဥ ဆရာ/အမတိ ့ ့Practice မာလည်း ဆီးချိ�အတွက် Diamicron MR ေသာကေနတဲ့ Patients
�
်
်
�ရဲ
�
�
်
�
တိ�င်းမ�ာ Preterax ကိလည်း တစခါတည်း Prescribe လပေပးပါလိ ့Request လပပါတယ်။
်
်
�
Up to 2 tablets daily 1 One tablet daily 2
With the same glass, at the same time
20 IF 0551 NA
1. SmPC of Diamicron ® MR.
2. SmPC of Preterax ® .
Diamicron ® MR is indicated in T2D in adults when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose.
Preterax ® 2.5 mg/0.625 mg is indicated for treatment of essential hypertension.
Preterax ® 5 mg/1.25 mg is indicated for treatment of essential hypertension in patients whose blood pressure is not adequately controlled on perindopril alone.
Preterax ® 10 mg/2.5 mg is indicated as a substitution therapy for treatment of essential hypertension in patients whose blood pressure is already controlled with perindopril and indapamide given concurrently at the same dose level. Please refer to your local SmPC for complete information.
http://www.mims.com/myanmar/drug/info/diamicron%20mr%2030-diamicron%20mr%2060/?type=brief , http://www.mims.com/myanmar/drug/info/preterax/?type=brief
DMR-C1-2021-002
23 24
4